BUDGET IMPACT ANALYSIS OF CRIZOTINIB IN THE TREATMENT OF ALK-POSITIVE NON-SMALL CELL LUNG CANCER IN THE BRAZILIAN PRIVATE HEALTH SYSTEM
Author(s)
Alexandre RF, Squiassi HB, Santana CF
Pfizer, São Paulo, Brazil
OBJECTIVES: To evaluate the budget impact of crizotinib, an oral inhibitor of anaplastic lymphoma kinase (ALK), in the treatment of ALK-positive non-small cell lung cancer (ALK+NSCLC) in the Brazilian private health system. METHODS: A budget-impact model was developed to compare the cost of treatment with crizotinib in ALK+NSCLC patients to that of chemotherapy (cisplatin, docetaxel, erlotinib, gemcitabine, paclitaxel and pemetrexed). Analysis considered a three year time horizon from the perspective of the BPHS, and has included only direct costs of medicines. Based on published data, the incidence rates considered to the Brazilian population were 0,014% of lung cancer (LC), 89,5% of NSCLC, 70,6% of advanced NSCLC and 5% of ALK+NSCLC, applied considering a health plan with applied an annual population growth rate of 0,9% after first year. Medicines cost’s data were taken from MoH’s price, November 2016. RESULTS: Total of LC patients were 280, 283 and 286 in years 1, 2 and 3 respectively, while the total of ALK+NSCLC patients were 9 in years 1, 2 and 10 in year 3. Costs of treatments, including crizotinib were BRL 34,752,443, BRL 35,105,866 and BRL 35,655,547 in years 1, 2 and 3 versus BRL 32,986,119, BRL 33,339,542 and BRL 33,692,964 only with chemotherapy, resulting in an incremental budget impact of BRL 1,766,324, BRL 1,766,324 and BRL 1,962,582, respectively. Over a three year time horizon, the incremental budget impact was BRL 5,495,231 (5% of LC patients) or BRL 0.08 per member per month from total lives of the Brazilian private health plan. CONCLUSIONS: Crizotinib is a novel targeted anticancer agent that favors ALK+NSCLC patients. Considering only the cost of drugs, treatment of ALK+NSCLC’s patients with crizotinib were associated with low budget impact to the Brazilian private health system.
Conference/Value in Health Info
2017-05, ISPOR 2017, Boston, MA, USA
Value in Health, Vol. 20, No. 5 (May 2017)
Code
PCN59
Topic
Economic Evaluation
Topic Subcategory
Budget Impact Analysis
Disease
Oncology